Hulya Halis
Research Subjects
Hulya Halis has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Selim Kurtoglu
Department of Pediatric Endocrinology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
5 shared publications - Mehmet Adnan Ozturk
Pediatrics and Neonatology, Erciyes University, Kayseri, TUR
4 shared publications - Osman Baştuğ
Division of Neonatology, Department of Pediatrics, Erciyes University Medical Faculty, Kayseri, Turkey
4 shared publications - Levent Korkmaz
Division of Neonatology, Department of Pediatrics, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, Turkey
3 shared publications - Sabriye Korkut
Division of Neonatology, Department of Pediatrics, Ankara Bilkent City Hospital, Ankara, Turkey
3 shared publications - Tamer Gunes
Department of Pediatrics, Faculty of Medicine, Erciyes University, Kayseri, Turkey
3 shared publications
Latest Publications
- Open Access
- 3 November 2022
- Published by Springer Nature in Cureus
- Vol. 14 (11) , e31088
A Retrospective Analysis of the Neurological Evaluation of Cases With Neonatal Hypoglycemia
Hypoglycemia is a common treatable metabolic disorder in the neonatal period. It can cause several neurological problems if untreated. In this study, the neurological outcomes of cases with hypoglycemia in the neonatal period were examined retrospectively, and the study aimed to determine risk factors and prognostic factors. In this retrospective study, cases were followed in the pediatric neurology outpatient clinic between 2019 and 2022, and patients with a history of hypoglycemia in the neonatal period were enrolled and analyzed retrospectively. The laboratory studies and clinical findings of the cases were obtained from follow-up records from the pediatric neurology outpatient clinic retrospectively. Physical examination findings, hypoglycemia levels, and symptoms of hypoglycemia, if any, were obtained retrospectively from the discharge files of the patients. A total of 70 cases were included in the study. Twenty-eight were girls and 42 were boys. Forty of the cases were preterm. The number of asymptomatic cases was 38, and the number of symptomatic cases was 32. There was no significant difference in regard to the mean lowest serum glucose levels between symptomatic and asymptomatic cases. Thirty-three of the patients had neurological problems such as neuromotor developmental delay, cortical blindness, and epilepsy. Abnormal magnetic resonance imaging (MRI) findings were detected in 30 of the symptomatic cases and eight of the asymptomatic cases. The rate of neurological sequelae in asymptomatic cases was found to be significantly lower than in symptomatic cases. Patients who have a symptomatic hypoglycemic period, maternal gestational problems, and abnormal MRI carry a high risk for neurological sequelae, and these findings indicate poor prognosis.
- 3 November 2022
- Published by Springer Nature in Cureus
- Vol. 14 (11) , e31088
Open AccessA Retrospective Analysis of the Neurological Evaluation of Cases With Neonatal Hypoglycemia
Hypoglycemia is a common treatable metabolic disorder in the neonatal period. It can cause several neurological problems if untreated. In this study, the neurological outcomes of cases with hypoglycemia in the neonatal period were examined retrospectively, and the study aimed to determine risk factors and prognostic factors. In this retrospective study, cases were followed in the pediatric neurology outpatient clinic between 2019 and 2022, and patients with a history of hypoglycemia in the neonatal period were enrolled and analyzed retrospectively. The laboratory studies and clinical findings of the cases were obtained from follow-up records from the pediatric neurology outpatient clinic retrospectively. Physical examination findings, hypoglycemia levels, and symptoms of hypoglycemia, if any, were obtained retrospectively from the discharge files of the patients. A total of 70 cases were included in the study. Twenty-eight were girls and 42 were boys. Forty of the cases were preterm. The number of asymptomatic cases was 38, and the number of symptomatic cases was 32. There was no significant difference in regard to the mean lowest serum glucose levels between symptomatic and asymptomatic cases. Thirty-three of the patients had neurological problems such as neuromotor developmental delay, cortical blindness, and epilepsy. Abnormal magnetic resonance imaging (MRI) findings were detected in 30 of the symptomatic cases and eight of the asymptomatic cases. The rate of neurological sequelae in asymptomatic cases was found to be significantly lower than in symptomatic cases. Patients who have a symptomatic hypoglycemic period, maternal gestational problems, and abnormal MRI carry a high risk for neurological sequelae, and these findings indicate poor prognosis.
- Open Access
- 21 July 2021
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (12) , 5590-5594
Evaluation of immunogenicity after first dose of hepatitis B vaccine in newborns with very low birth weight
Hepatitis-B virus (HBV) infection is an important health problem worldwide. HBV vaccine application varies according to the birth weight and gestational week in the neonatal period. This study aime...
- 21 July 2021
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (12) , 5590-5594
Open AccessEvaluation of immunogenicity after first dose of hepatitis B vaccine in newborns with very low birth weight
Hepatitis-B virus (HBV) infection is an important health problem worldwide. HBV vaccine application varies according to the birth weight and gestational week in the neonatal period. This study aime...
- Open Access
- 18 May 2018
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 10 (2) , 119-124
A Study of the Relationship Between Cystatin C and Metabolic Bone Disease in Preterm Infants
Objective: Cystatin C (CysC) is commonly used as a marker of renal failure in premature infants. The aim of this study was to investigate serum CysC levels in osteopenia of prematurity (OP) and determine whether CysC could be safely used as a marker of renal insufficiency in infants with OP. Methods: Subjects were 50 preterm infants (<= 32 gestational weeks). Calcium (Ca), phosphorus (P) and alkaline phosphatase (ALP) serum levels were measured in postnatal week nine, and bone density was measured concurrently by quantitative ultrasonography. Patients with a Z score of <-2 were considered to have OP. Results: The mean serum CysC levels in preterm infants in postnatal week nine were 1.50 +/- 0.19 mg/L. Serum CysC levels were not correlated with speed of sound values, Z scores, serum Ca, P or ALP levels. Serum CysC levels were not significantly different between infants with OP 11.50 (1.35-1.61) mg/L] and in infants without OP 11.58 (1.28-1.70) mg/L]. Conclusion: The presence of OP does not affect the safety of CysC as a marker of renal insufficiency in preterm infants.
- 18 May 2018
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 10 (2) , 119-124
Open AccessA Study of the Relationship Between Cystatin C and Metabolic Bone Disease in Preterm Infants
Objective: Cystatin C (CysC) is commonly used as a marker of renal failure in premature infants. The aim of this study was to investigate serum CysC levels in osteopenia of prematurity (OP) and determine whether CysC could be safely used as a marker of renal insufficiency in infants with OP. Methods: Subjects were 50 preterm infants (<= 32 gestational weeks). Calcium (Ca), phosphorus (P) and alkaline phosphatase (ALP) serum levels were measured in postnatal week nine, and bone density was measured concurrently by quantitative ultrasonography. Patients with a Z score of <-2 were considered to have OP. Results: The mean serum CysC levels in preterm infants in postnatal week nine were 1.50 +/- 0.19 mg/L. Serum CysC levels were not correlated with speed of sound values, Z scores, serum Ca, P or ALP levels. Serum CysC levels were not significantly different between infants with OP 11.50 (1.35-1.61) mg/L] and in infants without OP 11.58 (1.28-1.70) mg/L]. Conclusion: The presence of OP does not affect the safety of CysC as a marker of renal insufficiency in preterm infants.
- 14 February 2017
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 13 (5) , 479-484
Thyroid status of iodine deficient newborn infants living in central region of Turkey: a pilot study
Iodine deficiency (ID) during the fetal and neonatal periods can lead to neonatal hypothyroidism. This study was conducted to evaluate the effect of ID on the thyroid hormone level of newborns living in Turkey.
- 14 February 2017
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 13 (5) , 479-484
Thyroid status of iodine deficient newborn infants living in central region of Turkey: a pilot study
Iodine deficiency (ID) during the fetal and neonatal periods can lead to neonatal hypothyroidism. This study was conducted to evaluate the effect of ID on the thyroid hormone level of newborns living in Turkey.
- 1 September 2016
- Published by Elsevier in Medical Hypotheses
- Vol. 94, 77-80
In the diagnosis of neonatal sepsis importance of gelsolin and relationship with mortality and morbidity
- 1 September 2016
- Published by Elsevier in Medical Hypotheses
- Vol. 94, 77-80
In the diagnosis of neonatal sepsis importance of gelsolin and relationship with mortality and morbidity
- 10 November 2014
- Published by Wiley in Pediatrics International
- Vol. 56 (6) , 856-859
Predictive value of gelsolin for the outcomes of preterm neonates: A pilot study
Plasma gelsolin is a circulating actin-binding protein that has a protective role against tissue injuries. Our aim was to compare the baseline levels of gelsolin in premature infants with neonatal outcomes. A total of 32 preterm neonates born at 23-32 weeks of gestation were enrolled in the study. Plasma gelsolin levels at 72 h were significantly lower in patients with respiratory distress syndrome, in patients who were administered surfactant therapy and in patients who developed sepsis (P < 0.05). Plasma gelsolin levels at 28 days were significantly lower in patients who developed bronchopulmonary dysplasia and retinopathy of prematurity (P < 0.05). Low plasma gelsolin levels in the first postnatal month may be associated with poor outcomes in premature infants.
- 10 November 2014
- Published by Wiley in Pediatrics International
- Vol. 56 (6) , 856-859
Predictive value of gelsolin for the outcomes of preterm neonates: A pilot study
Plasma gelsolin is a circulating actin-binding protein that has a protective role against tissue injuries. Our aim was to compare the baseline levels of gelsolin in premature infants with neonatal outcomes. A total of 32 preterm neonates born at 23-32 weeks of gestation were enrolled in the study. Plasma gelsolin levels at 72 h were significantly lower in patients with respiratory distress syndrome, in patients who were administered surfactant therapy and in patients who developed sepsis (P < 0.05). Plasma gelsolin levels at 28 days were significantly lower in patients who developed bronchopulmonary dysplasia and retinopathy of prematurity (P < 0.05). Low plasma gelsolin levels in the first postnatal month may be associated with poor outcomes in premature infants.
- 20 January 2014
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 27 (9-10) , 997-9
Ovarian hyperstimulation syndrome treated by medroxyprogesterone acetate
The activation of the hypothalamic-pituitary-gonadal axis observed during the first month of life is thought to be a significant phase in the maturation of gonads and potentially be important for the development of reproductive functions. The preterm ovarian hyperstimulation syndrome (POHS) was first detected at postconception 36-39 weeks in a preterm female newborn with edema developing in the vulva, the hypogastric site, and the upper leg. The pathophysiology of this postnatal hormonal change is obscure. In this paper we would like to present a case developing POHS and to discuss possible pathophyslogical mechanisms.
- 20 January 2014
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 27 (9-10) , 997-9
Ovarian hyperstimulation syndrome treated by medroxyprogesterone acetate
The activation of the hypothalamic-pituitary-gonadal axis observed during the first month of life is thought to be a significant phase in the maturation of gonads and potentially be important for the development of reproductive functions. The preterm ovarian hyperstimulation syndrome (POHS) was first detected at postconception 36-39 weeks in a preterm female newborn with edema developing in the vulva, the hypogastric site, and the upper leg. The pathophysiology of this postnatal hormonal change is obscure. In this paper we would like to present a case developing POHS and to discuss possible pathophyslogical mechanisms.
- 1 January 2014
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 27 (7-8) , 745-8
Neonatal diabetes in an infant of diabetic mother: same novel INS missense mutation in the mother and her offspring
Neonatal diabetes is defined as an uncontrolled hyperglycemic state occurring within the first 6 months of life. It is a rare disease with an incidence of 1 to 90,000-250,000. It is usually a disease of genetic origin in which insulin gene mutations play the main role in the disease process. A baby, born to a mother who had previously been diagnosed with type 1 diabetes mellitus at 14 months of age, had a high blood sugar level within the first few hours after birth and was subsequently diagnosed as having neonatal diabetes mellitus. Baby and mother were identified as having a novel heterozygous insulin missense mutation, p.C109R. Difficulties occurred in both follow-up and feeding of the baby. Without the addition of the mother's milk, an appropriate calorie milk formula and isophane insulin were used for the baby during follow-up. Multiple mechanisms are responsible in the pathogenesis of neonatal diabetes mellitus. Insulin gene mutations are one of the factors in the development of neonatal diabetes mellitus. If a resistant hyperglycemic state persists for a long time among babies, especially in those with intrauterine growth retardation whose mothers are diabetic, the baby concerned should be followed-up carefully for the development of neonatal diabetes mellitus.
- 1 January 2014
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 27 (7-8) , 745-8
Neonatal diabetes in an infant of diabetic mother: same novel INS missense mutation in the mother and her offspring
Neonatal diabetes is defined as an uncontrolled hyperglycemic state occurring within the first 6 months of life. It is a rare disease with an incidence of 1 to 90,000-250,000. It is usually a disease of genetic origin in which insulin gene mutations play the main role in the disease process. A baby, born to a mother who had previously been diagnosed with type 1 diabetes mellitus at 14 months of age, had a high blood sugar level within the first few hours after birth and was subsequently diagnosed as having neonatal diabetes mellitus. Baby and mother were identified as having a novel heterozygous insulin missense mutation, p.C109R. Difficulties occurred in both follow-up and feeding of the baby. Without the addition of the mother's milk, an appropriate calorie milk formula and isophane insulin were used for the baby during follow-up. Multiple mechanisms are responsible in the pathogenesis of neonatal diabetes mellitus. Insulin gene mutations are one of the factors in the development of neonatal diabetes mellitus. If a resistant hyperglycemic state persists for a long time among babies, especially in those with intrauterine growth retardation whose mothers are diabetic, the baby concerned should be followed-up carefully for the development of neonatal diabetes mellitus.